Ambrilia To Announce U.S. Octreotide Partner By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
The Canadian company will pair with Teva in Europe on its formulation of Novartis’ acromegaly therapy Sandostatin LAR.